EP1315717A1 - Chinazolin derivate , diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung - Google Patents
Chinazolin derivate , diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellungInfo
- Publication number
- EP1315717A1 EP1315717A1 EP01962953A EP01962953A EP1315717A1 EP 1315717 A1 EP1315717 A1 EP 1315717A1 EP 01962953 A EP01962953 A EP 01962953A EP 01962953 A EP01962953 A EP 01962953A EP 1315717 A1 EP1315717 A1 EP 1315717A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino
- oxo
- buten
- chloro
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to bicyclic heterocycles of the general formula
- R a is a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R- L and R 2 , where
- R- L represents a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyan or ethynyl group and R 2 represents a hydrogen or fluorine atom,
- R b is an R 3 O-CO-CH 2 -N-CH 2 -CH 2 -OH group which is optionally substituted on the methylene groups by 1 or 2 methyl or ethyl groups, where
- R 3 is a hydrogen atom or a C 1 . 4 represents alkyl group, a 2-oxomorpholin-4-yl group which can be substituted by 1 or 2 methyl or ethyl groups, or
- R c is a hydrogen atom, a methoxy, ethoxy, 2-methoxy-ethoxy, 2-ethoxyethoxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, tetrahydrofuran.
- n is an integer from 1 to 3 with the proviso that the following compounds
- R a is a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R x and R 2 , where
- R represents a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyan or ethynyl group and R 2 represents a hydrogen or fluorine atom
- R b is an R 3 O-CO-CH 2 -N-CH 2 -CH 2 -OH group which is optionally substituted on the methylene groups by 1 or 2 methyl or ethyl groups, where
- R 3 represents a hydrogen atom or a C - ⁇ - alkyl group
- R c is a hydrogen atom, a methoxy, ethoxy, 2-methoxyethoxy, 2-ethoxyethoxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, tetrahydrofuran
- n is an integer from 1 to 3 with the proviso that the following compounds
- R a is a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R x and R 2 , where
- R ⁇ a fluorine, chlorine or bromine atom, a methyl or ethynyl group
- R 2 represents a hydrogen or fluorine atom
- R b is an R 3 O-CO-CH 2 -N-CH 2 -CH 2 -OH group substituted on the methylene groups by 1 or 2 methyl or ethyl groups, where
- R 3 is a C 1 . 4 represents alkyl group
- R c is a hydrogen atom, a methoxy, ethoxy, 2-methoxyethoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl ethoxy- or tetrahydrooxy or tetrahydro group and
- R a is a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R- L and R 2 , where
- R- L is a fluorine, chlorine or bromine atom
- R 2 represents a hydrogen or fluorine atom
- R b is a 2-oxomorpholin-4-yl group which is substituted by 1 or 2 methyl or ethyl groups
- R c is a hydrogen atom, a methoxy, ethoxy, 2-methoxy-ethoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, tetra-hydrofuranylmethoxy or tetrahydropyranylmethoxy group
- R a is a 1-phenylethyl or a 3-chloro-4-fluorophenyl group
- R b is a 2-oxomorpholin-4-yl group which is substituted by 1 or 2 methyl groups, or
- R c is a hydrogen atom, a methoxy, 2-methoxyethoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl methoxy or tetrahydropyranylmethoxy group and
- the compounds of the general formula I can be prepared, for example, by the following processes:
- R b and n are defined as mentioned at the outset and Z x represents a leaving group such as a halogen atom, for example a chlorine or bromine atom, or a hydroxyl group.
- the reaction is optionally carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, acetonitrile, toluene, chlorobenzene, tetrahydrofuran, methylene chloride / tetrahydrofuran or dioxane, optionally in the presence of an inorganic or organic base and optionally in the presence of a dehydrating agent, at temperatures between -50 and 150 ° C, preferably at temperatures between -20 and 80 ° C.
- a solvent or solvent mixture such as methylene chloride, dimethylformamide, acetonitrile, toluene, chlorobenzene, tetrahydrofuran, methylene chloride / tetrahydrofuran or dioxane
- the reaction is optionally carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, acetonitrile, toluene, chlorobenzene, tetrahydrofuran, methylene chloride / tetrahydrofuran or dioxane in the presence of a tertiary organic base such as Triethylamine, pyridine, 2-dimethylaminopyridine, or N-ethyl-diisopropylamine (Hünig base), where these organic bases can also serve as solvents at the same time, or in the presence of an inorganic base such as sodium carbonate, potassium carbonate or sodium hydroxide preferably at temperatures between -50 and 150 ° C, preferably at temperatures between -20 and 80 ° C, performed.
- a solvent or solvent mixture such as methylene chloride, dimethylformamide, acetonitrile, toluene, chlorobenzene, tetrahydrofuran, methylene chlor
- the reaction is preferably carried out in the presence of a dehydrating agent, for example in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, hexamethyldisilazane, N, N ' -Dicyclohexylcarbodiimide, N, N '-dicyclohexylcar- bodiimide / N-hydroxysuccinimide or 1-hydroxy-benzotriazole and optionally additionally in the presence of 4-dimethylamino-pyridine, N, N '-carbonyldiimidazole or triphenylphosphine / carbon tetrachloride expediently in a solvent such as methylene chloride, tetrahydrofuran, dioxane, toluene, Chlorobenzene
- a dehydrating agent for example in the presence of isobutyl chloro
- R a , R c and n are defined as mentioned at the beginning and
- Z2 represents a leaving group such as a halogen atom or a substituted sulfonyloxy group such as a chlorine or bromine atom, a methanesulfonyloxy or p-toluenesulfonyloxy group or a hydroxy group, with a compound of the general formula
- R b is defined as mentioned at the beginning
- the reaction is conveniently carried out in a solvent such as isopropanol, acetonitrile, butanol, tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethyl sulfoxide, methylene chloride, ethylene glycol monomethyl ether, ethylene glycol diethyl ether or sulfolane or in a solvent mixture, optionally in the presence of an inorganic base, for example sodium carbonate or potassium hydroxide, or a tertiary organic base, for example triethylamine or N-ethyl-diisopropylamine (Hünig base), these organic bases simultaneously also as Solvents can serve, and optionally in the presence of a reaction accelerator such as an alkali metal halide at temperatures between -20 and 150 ° C, but preferably at temperatures between -10 and 100 ° C.
- a reaction accelerator such as an alkali metal halide at temperatures between -20 and
- the reaction is preferably carried out in the presence of an activating agent, for example in the presence of thionyl chloride or phosphorus trichloride, advantageously in a solvent such as acetonitrile, methylene chloride, tetrahydrofuran, dioxane, toluene, chlorobenzene or ethylene glycol diethyl ether and optionally in the presence of a reaction accelerator such as sodium iodide at temperatures between -50 and 150 ° C, but preferably at temperatures between -20 and 80 ° C.
- an activating agent for example in the presence of thionyl chloride or phosphorus trichloride, advantageously in a solvent such as acetonitrile, methylene chloride, tetrahydrofuran, dioxane, toluene, chlorobenzene or ethylene glycol diethyl ether
- a reaction accelerator such as sodium iodide at temperatures between -50 and 150 ° C, but
- the compound of formula IV can also be prepared in a one-pot process from the compound of formula II and a corresponding carboxylic acid derivative and directly reacted further.
- R a , R c and n - are defined as mentioned at the outset, and R b 'is an optionally substituted N- (carboxymethyl) -N- (2) which can be converted into an optionally substituted 2-oxomorpholin-4-yl group by cyclization -hydroxyethyl) amino or N- (C 1, 4- alkyloxycarbonylmethyl) -N- (2-hydroxyethyl) amino group.
- the reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, acetonitrile, dimethylformamide, dimethyl sulfoxide, sulfolane, benzene, toluene, chlorenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane in the presence of an anhydrous acid such as trifluoroacetic acid, methanesulfonic acid or in the presence of a sulfuric acid or in sulfuric acid dehydrating agent, e.g.
- a solvent or mixture of solvents such as methylene chloride, acetonitrile, dimethylformamide, dimethyl sulfoxide, sulfolane, benzene, toluene, chlorenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane
- an anhydrous acid such as trifluoroacetic acid
- Formula I which contains an optionally substituted 2-oxomorpholino-4-yl group, can be converted by hydrolysis into a corresponding compound which is an optionally substituted N- (carboxymethyl) -N- (2-hydroxy - Contains ethyl) amino group.
- the optionally subsequent hydrolysis is carried out, for example, hydrolytically in an aqueous solvent, for example in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as Sodium hydroxide at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.
- an aqueous solvent for example in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as Sodium hydroxide at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.
- any reactive groups present such as hydroxyl, carboxy or imino groups, can be protected during the reaction by customary protective groups, which are split off again after the reaction.
- the trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert-butyl, trityl, benzyl or tetrahydropyranyl group comes as a protective radical for a hydroxyl group
- the formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-ethoxybenzyl group are considered.
- the subsequent subsequent splitting off of a protective residue used takes place, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as sodium hydroxide or potassium hydroxide or aprotic, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.
- an aqueous solvent e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water
- an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid
- an alkali base
- a benzyl, methoxybenzyl or benzyloxycarbonyl radical is split off, for example by hydrogenolysis, for example using hydrogen in the presence of a catalyst such as palladium / carbon in a suitable solvent such as methanol, Ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 ° C, but preferably at room temperatures between 20 and 60 ° C, and at a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar.
- a 2,4-dimethoxybenzyl radical is preferably cleaved in trifluoroacetic acid in the presence of anisole.
- a tert-butyl or tert-butyloxycarbonyl radical is preferably cleaved off by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or diethyl ether.
- a trifluoroacetyl radical is preferably cleaved by treatment with an acid such as hydrochloric acid, if appropriate in the presence of a solvent such as acetic acid at temperatures between 50 and 120 ° C. or by treatment with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 ° C. ,
- the compounds of general formula I obtained can be separated into their enantiomers and / or diastereomers.
- cis / trans mixtures can be separated into their ice and trans isomers, and compounds with at least one optically active carbon atom can be separated into their enantiomers.
- the cis / trans mixtures obtained can be chromatographed into their eis and trans isomers, the compounds of general formula I obtained which occur in racemates, according to methods known per se (see Allinger NL and Eliel EL in “Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971)) in their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms due to their physically Separate chemical differences into their diastereomers by methods known per se, for example by chromatography and / or fractional crystallization, which, if they occur in racemic form, can then be separated into the enantiomers as mentioned above.
- the separation of enantiomers is preferably carried out by column separation on chiral phases or by recrystallization from an optically active solvent or by reaction with a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols, and separation of the diastereomeric salt mixture or derivative thus obtained, e.g. due to different solubilities, it being possible for the free antipodes to be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
- a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols
- Suitable optically active alcohols are, for example, (+) - or (-) menthol, and optically active acyl radicals in amides are, for example, (+) or (-) menthyloxycarbonyl.
- the compounds of the formula I obtained can be converted into their salts, in particular for pharmaceutical use into their physiologically tolerable salts with inorganic or organic acids.
- suitable acids for this purpose are hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
- the compounds of the general formula I according to the invention and their physiologically tolerated salts have valuable pharmacological properties, in particular an inhibitory effect on the signal transduction mediated by the epidermal growth factor receptor (EGF-R), this being achieved, for example, by inhibiting the Ligand binding, the receptor dimerization or the tyrosine kinase itself can be effected. It is also possible that the signal transmission on further downstream components may be blocked.
- EGF-R epidermal growth factor receptor
- EGF-R mediated signal transmission can e.g. can be detected with cells that express human EGF-R and whose survival and proliferation depends on stimulation by EGF or TGF-alpha.
- An interleukin-3 (IL-3) -dependent cell line of murine origin was used here, which has been genetically modified in such a way that it expresses functional human EGF-R.
- the proliferation of these cells called F / L-HERc can therefore be stimulated either by murine IL-3 or by EGF (see von Rüden, T. et al. In EMBO J. 2, 2749-2756 (1988) and Pierce, JH et al. In Science Ia, 628-631 (1988)).
- the FDC-Pi ⁇ cell line was used as the starting material for the F / L-HERc cells. Their production by Dexter, TM et al. in J. Exp. Med. 152, 1036-1047 (1980). Alternatively, other growth factor-dependent cells can also be used (see, for example, Pierce, JH et al. In Science 2J12, 628-631 (1988), Shibuya, H. et al. In Cell 2S,
- F / L-HERc cells were in RPMI / 1640 medium (BioWhittaker), supplemented with 10% fetal bovine serum (FCS, Boehringer Mannheim), 2 mM glutamine (BioWhittaker), standard antibiotics and 20 ng / ml human EGF (Promega), at 37 ° C and 5% CO 2 cultivated.
- FCS fetal bovine serum
- FCS Boehringer Mannheim
- 2 mM glutamine BioWhittaker
- standard antibiotics 20 ng / ml human EGF (Promega)
- 20 ng / ml human EGF Promega
- the relative cell number was determined using the Cell
- the compounds of the general formula I according to the invention thus inhibit signal transduction by tyrosine kinases, as has been shown using the example of the human EGF receptor, and are therefore useful for the treatment of pathophysiological processes which are caused by overactive tyrosine kinases.
- tyrosine kinases e.g. benign or malignant tumors, in particular tumors of epithelial and neuroepithelial origin, metastasis and the abnormal proliferation of vascular endothelial cells (neoangiogenesis).
- the compounds of the invention are also useful for the prevention and treatment of respiratory and lung diseases associated with increased or altered mucus production caused by stimulation of tyrosine kinases such as e.g. for inflammatory diseases of the respiratory tract such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, ⁇ l-antitrypsin deficiency, or for cough, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.
- tyrosine kinases such as e.g. for inflammatory diseases of the respiratory tract such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, ⁇ l-antitrypsin deficiency, or for cough, pulmonary
- the compounds are also suitable for the treatment of diseases of the gastrointestinal tract and the bile ducts and
- tyrosine kinases that is associated with impaired activity of the tyrosine kinases, such as those found in chronic inflammatory changes, such as cholecystitis, Crohn's disease, ulcerative colitis, and ulcers in the gastrointestinal tract or as in gastrointestinal disorders Tracts that are associated with increased secretion, such as M.
- Menetrier secreting adenomas and protein loss syndromes, furthermore for the treatment of nasal polyps as well as polyps of the gastrointestinal tract of different origins such as villous or adenomatous polyps of the colon, but also of polyps in familial polyposis coli, in intestinal polyps as part of the Gardner syndrome, in polyps in the entire gastrointestinal tract at Peutz -Jeghers syndrome, for inflammatory pseudopolypes, for juvenile polyps, for colitis cystica profunda and for pneumatosis cystoides intestinales.
- kidney diseases in particular in the case of cystic changes such as in cystic kidneys
- kidney cysts which may be of idiopathic origin or occur in the context of syndromes such as e.g. tuberous sclerosis, von Hippel-Lindau syndrome, nephronophthisis and marrow sponge kidney, and other diseases caused by aberrant function of tyrosine kinases, such as epidermal hyperproliferation (psoriasis), inflammatory processes, diseases of the immune system, hyperproliferation of hematopoietic cells etc.
- psoriasis epidermal hyperproliferation
- inflammatory processes diseases of the immune system
- hyperproliferation of hematopoietic cells etc.
- the compounds according to the invention can be used alone or in combination with other pharmacologically active compounds, for example in tumor therapy in monotherapy or in combination with other anti-tumor therapeutic agents, for example in combination with topoisomerase inhibitors (for example eto poside), mitosis inhibitors (e.g. vinblastine), compounds interacting with nucleic acids (e.g. cis-platinum, cyclophosphamide, adriamycin), hormone antagonists (e.g. tamoxifen), inhibitors of metabolic processes (e.g. 5-FU etc.), cytokines (e.g. interferons ), Antibodies, etc.
- topoisomerase inhibitors for example eto poside
- mitosis inhibitors e.g. vinblastine
- compounds interacting with nucleic acids e.g. cis-platinum, cyclophosphamide, adriamycin
- hormone antagonists e.g. tamoxi
- these compounds can be used alone or in combination with other respiratory therapies, such as secretolytic, broncholytic and / or anti-inflammatory. seeds are used.
- these compounds can likewise be given alone or in combination with substances which influence motility or secretion or which inhibit inflammation. These combinations can be administered either simultaneously or sequentially.
- These compounds can be used either alone or in combination with other active compounds, intravenously, subcutaneously, intramuscularly, intrarectally, intraperitoneally, intranasally, by inhalation or transdermally or orally, aerosol formulations in particular being suitable for inhalation.
- the compounds according to the invention are generally used in warm-blooded vertebrates, in particular in humans, in doses of 0.01-100 mg / kg body weight, preferably 0.1-15 mg / kg.
- these are mixed with one or more conventional inert carriers and / or diluents, e.g.
- R f value 0.54 (silica gel, ethyl acetate)
- reaction mixture is then stirred for a further 30 minutes at 10 ° C., then 31.19 g of 4- [(3-chloro-4-fluorophenyl) amino] -7-fluoro-6-nitro-quinazoline are added in portions, the temperature again should not exceed 15 ° C.
- the deep red reaction mixture is stirred for a further hour at 15 ° C.
- the batch is poured onto 2.5 l of water and neutralized with 2N hydrochloric acid.
- Example V (2-Hydroxy-2-methyl-propylamino) ethyl acetate
- 100.00 g of sodium carbonate are added with cooling.
- the resulting mass is extracted several times with a total of about 600 ml of diethyl ether.
- the combined ether extracts are dried over sodium sulfate and evaporated to dryness.
- VT VT
- Example: 1 4- [(3-chloro-4-fluorophenyl) amino] -6- [(4- ⁇ N- [(tert. Butyloxycarbonyl) methyl] -N- ((S) -2-hydroxy-prop- l-yl) -amino ⁇ -l-oxo-2-buten-1-yl) mino] -7-cyc] opropyl ethoxy-quinazoline
- the crude bromocrotonic acid chloride is taken up in 10 ml of methylene chloride and, with ice bath cooling, within five minutes to a solution of 1.00 g of 6-amino-4- [(3-chloro-4-fluorophenyl) amino] -7-cyclopropylmethoxy -quinazoline and 2.5 ml of diisopropylethylamine added dropwise in 30 ml of tetrahydrofuran.
- the reaction mixture is stirred for one hour while cooling with an ice bath, then for two hours at room temperature.
- the starting material used is (2-hydroxy-1,1-dimethyl-ethyl-amino) -acetic acid ethyl ester hydrochloride. The cyclized product is formed)
- the starting material used is (2-hydroxy-1,1-dimethylethylamino) ethyl acetate hydrochloride. The cyclized product is formed.
- the starting material used is (2-hydroxy-1,1-dimethylethylamino) acetic acid ethyl ester hydrochloride. The cyclized product is formed)
- the starting material used is (2-hydroxy-1,1-dimethylethylamino) ethyl acetate hydrochloride. The cyclized product is formed.
- the starting material used is (2-hydroxy-1,1-dimethyl-ethyl-amino) -acetic acid ethyl ester hydrochloride. The cyclized product is formed)
- R f value 0.49 (aluminum oxide, ethyl acetate)
- reaction mixture is evaporated to dryness.
- the flask residue is distributed between ethyl acetate and saturated ⁇ carbonate solution.
- the organic phase is separated off, washed with saturated sodium carbonate solution, water and saturated sodium chloride solution, dried over magnesium sulfate and concentrated.
- the substance is obtained by treating a methanol solution of 4- [(3-chloro-4-fluorophenyl) amino] -6- ⁇ [4- ((R) -6-methyl-2-oxo-morpholin-4-yl ) -l-oxo-2-buten-l-yl] amino) -7-cyclopropylmethoxy-quinazoline with ethereal hydrochloric acid at room temperature.
- 1 coated tablet contains:
- the active substance is mixed with calcium phosphate, corn starch, polyvinyl pyrrolidone, hydroxypropyl methyl cellulose and half of the stated amount of magnesium stearate. Pressings with a diameter of approx. 13 mm are produced on a tabletting machine, these are rubbed on a suitable machine through a sieve with a 1.5 mm mesh size and mixed with the remaining amount of magnesium stearate. This granulate is pressed on a tablet machine into tablets of the desired shape.
- the dragee cores thus produced are coated with a film consisting essentially of hydroxypropylmethyl cellulose.
- the finished film coated tablets are polished with beeswax.
- 1 tablet contains:
- Active ingredient, milk sugar and starch are mixed and moistened uniformly with an aqueous solution of the polyvinylpyrrolidone. After sieving the moist mass (2.0 mm mesh size) and drying in a rack drying cabinet at 50 ° C, sieving takes place again (1.5 mm mesh size) and the lubricant is added. The ready-to-press mixture is processed into tablets.
- Tablet weight 220 mg, diameter: 10 mm, biplane with a facet on both sides and a partial notch on one side.
- 1 tablet contains:
- the active substance mixed with milk sugar, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a sieve with a mesh size of 1.5 mm.
- the granules dried at 45 ° C are again rubbed through the same sieve and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.
- 1 capsule contains:
- the active ingredient is mixed with the excipients through a
- the final mix is filled into size 1 hard gelatin capsules. Capsule filling: approx. 320 mg
- Capsule shell hard gelatin capsule size 1.
- 1 suppository contains:
- Polyethylene glycol 1500 550.0 mg
- the active ingredient is homogeneously distributed therein and the melt is poured into pre-cooled molds.
- Carboxymethylcellulose Na salt 0.10 g p-hydroxybenzoic acid methyl ester 0.05 g p-hydroxybenzoic acid propyl ester 0.01 g
- Sorbitol solution 70% 20.00 g aroma 0.30 g
- Dest. Water is heated to 70 ° C. P-Hydroxybenzoic acid methyl ester and propyl ester as well as glycerol and carboxymethyl cellulose sodium salt are dissolved therein with stirring. It is cooled to room temperature and the active ingredient is added with stirring and dispersed homogeneously. After adding and dissolving the sugar, the sorbitol solution and the aroma, the suspension is evacuated with stirring for deaeration.
- 5 ml of suspension contain 50 mg of active ingredient.
- the active substance is dissolved in the required amount of 0.01N HCl, made isotonic with sodium chloride, sterile filtered and filled into 2 ml ampoules.
- the active substance is dissolved in the required amount of 0.01N HCl, made isotonic with sodium chloride, sterile filtered and filled into 10 ml ampoules.
- 1 capsule contains:
- H ⁇ r-position The active substance is mixed with lactose for inhalation purposes. The mixture is filled into capsules on a capsule machine (weight of the empty capsule approx. 50 mg). Capsule weight: 70.0 mg Capsule size: 3
- 1 hub includes:
- the active substance and benzalkonium chloride are dissolved in ethanol / water (50/50).
- the pH of the solution is adjusted with 1N hydrochloric acid.
- the adjusted solution is filtered and filled into containers (cartridges) suitable for manual mistake.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10042060 | 2000-08-26 | ||
DE10042060A DE10042060A1 (de) | 2000-08-26 | 2000-08-26 | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
PCT/EP2001/009537 WO2002018373A1 (de) | 2000-08-26 | 2001-08-18 | Chinazolin derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1315717A1 true EP1315717A1 (de) | 2003-06-04 |
Family
ID=7653947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01962953A Withdrawn EP1315717A1 (de) | 2000-08-26 | 2001-08-18 | Chinazolin derivate , diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1315717A1 (de) |
JP (1) | JP2004517048A (de) |
AU (1) | AU2001284021A1 (de) |
CA (1) | CA2417050C (de) |
DE (1) | DE10042060A1 (de) |
MX (1) | MXPA03000873A (de) |
WO (1) | WO2002018373A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE04748B1 (et) | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
TW200813014A (en) | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
DE10307165A1 (de) * | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
ES2279441T3 (es) | 2003-09-19 | 2007-08-16 | Astrazeneca Ab | Derivados de quinazolina. |
MXPA06009475A (es) | 2004-02-19 | 2007-05-15 | Rexahn Corp | Derivados de quinazolina y usos terapeuticos de los mismos. |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
TW200640904A (en) | 2005-02-26 | 2006-12-01 | Astrazeneca Ab | Quinazoline derivatives |
WO2007055513A1 (en) * | 2005-11-08 | 2007-05-18 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof |
KR100832593B1 (ko) * | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법 |
WO2007054550A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
DK2068880T3 (da) | 2006-09-18 | 2012-07-23 | Boehringer Ingelheim Int | Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
WO2008095847A1 (de) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
AU2009247782C1 (en) | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
TWI385174B (zh) | 2008-11-10 | 2013-02-11 | Nat Health Research Institutes | 作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物 |
SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
PH12012500097A1 (en) * | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
CN102382106A (zh) * | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
WO2013135176A1 (zh) * | 2012-03-16 | 2013-09-19 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
WO2018095353A1 (en) * | 2016-11-25 | 2018-05-31 | Sunshine Lake Pharma Co., Ltd. | Salts of aminoquinazoline derivative and uses thereof |
CN115894455B (zh) * | 2021-09-30 | 2024-04-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
SK12112001A3 (sk) * | 1999-02-27 | 2001-12-03 | Boehringer Ingelheim Pharma Kg | 4-amino-chinazolínové a chinolínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
EE04748B1 (et) * | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks |
DE19928281A1 (de) * | 1999-06-21 | 2000-12-28 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10017539A1 (de) * | 2000-04-08 | 2001-10-11 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2000
- 2000-08-26 DE DE10042060A patent/DE10042060A1/de not_active Withdrawn
-
2001
- 2001-08-18 WO PCT/EP2001/009537 patent/WO2002018373A1/de active Application Filing
- 2001-08-18 JP JP2002523888A patent/JP2004517048A/ja active Pending
- 2001-08-18 AU AU2001284021A patent/AU2001284021A1/en not_active Abandoned
- 2001-08-18 MX MXPA03000873A patent/MXPA03000873A/es unknown
- 2001-08-18 EP EP01962953A patent/EP1315717A1/de not_active Withdrawn
- 2001-08-18 CA CA002417050A patent/CA2417050C/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO0218373A1 * |
Also Published As
Publication number | Publication date |
---|---|
DE10042060A1 (de) | 2002-03-07 |
AU2001284021A1 (en) | 2002-03-13 |
CA2417050C (en) | 2009-04-14 |
WO2002018373A1 (de) | 2002-03-07 |
CA2417050A1 (en) | 2002-03-07 |
JP2004517048A (ja) | 2004-06-10 |
MXPA03000873A (es) | 2003-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1315718B1 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
EP1315717A1 (de) | Chinazolin derivate , diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
EP1731511B1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
EP1315720B1 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
EP1280798B1 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
WO2002018351A1 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und vefahren zu ihrer herstellung | |
EP1345910B9 (de) | Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
DE60022866T2 (de) | Bizyklische heterozyklen, diese verbindungen enthaltende zusammenstellungen und verfahren zu deren herstellung | |
US6653305B2 (en) | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | |
EP1966189A1 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
WO2002018370A1 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
DE10307165A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung | |
EP1921070A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung | |
EP1641767A2 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
EP1322645A2 (de) | Chinazoline, diese verbindungen enthaltende als tyrosinkinase inhibitoren wirksame arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
DE10017539A1 (de) | Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
DE19911366A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
DE19928281A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
DE10040525A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
DE10023085A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030326 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BOEHRINGER INGELHEIM PHARMA KG & CO. KG |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SOLCA, FLAVIO Inventor name: BLECH, STEFAN Inventor name: JUNG, BIRGIT Inventor name: LANGKOPF, ELKE Inventor name: HIMMELSBACH, FRANK |
|
17Q | First examination report despatched |
Effective date: 20090114 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090725 |